kabutan

SymBio Pharma, First Half Net Income Loss Widens, Apr-Jun Net Income Loss Widens

Thu Jul 31, 2025 3:30 pm JST Earnings

4582 SymBio Pharmaceuticals Limited 【J-GAAP】

Earnings Report

SymBio Pharmaceuticals Limited <4582> [TSE Growth] announced its financial results after the market closed on July 31st (15:30). The consolidated net loss for the cumulative second quarter of the fiscal year ending December 2025 (January to June) expanded to a loss of 2.36 billion yen (compared to a loss of 1.54 billion yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net loss for the July to December period (second half) is expected to nearly flat at loss of 2.22 billion yen (compared to a loss of 2.29 billion yen in the same period last year).

In the most recent three-month period, from April to June (2Q), the consolidated net loss expanded to a loss of 1.04 billion yen (compared to a loss of 0.76 billion yen in the same period last year). The operating profit/loss margin drastically worsened from -132.9% in the same period last year to -257.9%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Jun, 2023 3,178 -49 66 -79 -2.0 ー Aug 3, 2023 J-GAAP
Jan - Jun, 2024 1,284 -1,719 -1,481 -1,541 -34.8 ー Aug 1, 2024 J-GAAP
Jan - Jun, 2025 646 -2,154 -2,340 -2,369 -49.4 ー Jul 31, 2025 J-GAAP
YoY -49.7% -25.3% -58.0% -53.7% -42.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jan - Jun, 2025 Guidance ー ー ー ー － 0 Feb 6, 2025 J-GAAP
Jan - Jun, 2025 Results 646 -2,154 -2,340 -2,369 -49.4 0 Jul 31, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 1,168 -2,157 -2,208 -2,292 -50.8 0 Feb 6, 2025 J-GAAP
Jul - Dec, 2025 Guidance 754 -2,108 -2,127 -2,223 -40.8 0 Jul 31, 2025 J-GAAP
YoY -35.4% +2.3% +3.7% +3.0% +19.8%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 5,589 -811 -736 -1,962 -49.2 0 Feb 8, 2024 J-GAAP
Dec, 2024 2,452 -3,876 -3,689 -3,833 -85.0 0 Feb 6, 2025 J-GAAP
Dec, 2025 Guidance 1,400 -4,262 -4,467 -4,592 -84.2 0 Jun 10, 2025 J-GAAP
YoY -42.9% -10.0% -21.1% -19.8% +1.0%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Apr - Jun, 2024 687 -913 -754 -764 -17.2 -132.9 Aug 1, 2024 J-GAAP
Jul - Sep, 2024 614 -1,072 -1,278 -1,304 -29.1 -174.6 Oct 31, 2024 J-GAAP
Oct - Dec, 2024 554 -1,085 -930 -988 -21.9 -195.8 Feb 6, 2025 J-GAAP
Jan - Mar, 2025 264 -1,169 -1,288 -1,321 -28.0 -442.8 May 8, 2025 J-GAAP
Apr - Jun, 2025 382 -985 -1,052 -1,048 -21.8 -257.9 Jul 31, 2025 J-GAAP
YoY -44.4% -7.9% -39.5% -37.2% -26.7%

Related Articles